Evidence map›Paper›PMID 32216516›Full record

ArticleLupus2020

Anti-vimentin antibodies: a unique antibody class associated with therapy-resistant lupus nephritis.

Andrew J Kinloch, Matthew D Cascino, Jian Dai, Rene S Bermea, Kichul Ko, Margaret Vesselits, Leonard L Dragone, Nirit Mor Vaknin, Maureen Legendre, David M Markovitz and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lupus, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Cellular aspects of the pathogenesis of lupus nephritis.Current opinion in rheumatology · 2021
    Review
  4. Review
  5. Article
  6. Machine Learning to QuantifyFrontiers in immunology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Andrew J KinlochGwen Knapp Center for Lupus and Immunology Research, University of Chicago, Section of Rheumatology and Department of Medicine, Chicago, USA.ORCID https://orcid.org/0000-0002-6827-4038
Matthew D CascinoProduct Development I20, Genentech Research & Early Development, South San Francisco, USA.
Jian DaiEarly Clinical Development Informatics, Genentech Research & Early Development, South San Francisco, USA.
Rene S BermeaUniversity of Chicago, Section of Rheumatology and Department of Medicine, Chicago, USA.
Kichul KoUniversity of Chicago, Section of Rheumatology and Department of Medicine, Chicago, USA.
Margaret VesselitsGwen Knapp Center for Lupus and Immunology Research, University of Chicago, Section of Rheumatology and Department of Medicine, Chicago, USA.
Leonard L DragoneEarly Development, Infectious Disease, The Janssen Pharmaceutical Companies of Johnson & Johnson, South San Francisco, California.
Nirit Mor VakninDepartment of Internal Medicine, University of Michigan, Ann Arbor, USA.
Maureen LegendreDepartment of Internal Medicine, University of Michigan, Ann Arbor, USA.
David M MarkovitzDepartment of Internal Medicine, University of Michigan, Ann Arbor, USA.
Michael K OkoreehGwen Knapp Center for Lupus and Immunology Research, University of Chicago, Section of Rheumatology and Department of Medicine, Chicago, USA.
Michael J TownsendBiomarker Discovery OMNI, Genentech Research & Early Development, South San Francisco, USA.
Marcus R ClarkGwen Knapp Center for Lupus and Immunology Research, University of Chicago, Section of Rheumatology and Department of Medicine, Chicago, USA.
University of Chicago · USUniversity of Michigan · USJohnson & Johnson (United States) · US

Funding

Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)T32HD007009 · NICHD · UNIVERSITY OF CHICAGO · PI NANCY B SCHWARTZ · 1985 to 2026
$13.0M
University of Chicago Autoimmunity Center of ExcellenceU19AI082724 · NIAID · UNIVERSITY OF CHICAGO · PI CLARK, MARCUS RAMSAY · 2009 to 2023
$7.2M
Tertiary Lymphoid Neogenesis in Human Lupus NephritisR01AR055646 · NIAMS · UNIVERSITY OF CHICAGO · PI CLARK, MARCUS RAMSAY · 2008 to 2018
$3.4M
NIAID NIH HHS U19 AI082724NIAMS NIH HHS R01 AR055646NICHD NIH HHS T32 HD007009
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAged, 80 and overAutoantibodiesCross-Sectional StudiesDrug ResistanceEnzyme InhibitorsFemaleHumansImmunoglobulin IsotypesImmunologic FactorsLupus Erythematosus, SystemicLupus NephritisMaleMiddle AgedMycophenolic AcidAutoantibodiesEnzyme InhibitorsImmunoglobulin IsotypesImmunologic FactorsMycophenolic AcidRituximabVimentinautoantibodieslupus nephritisprognosissystemic lupus erythematosusVimentin

Identifiers

PMID32216516
PMCPMC7278023
OpenAlexW3013337875

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.